NCT05846373View on ClinicalTrials.gov

Effect of Nicotinic Acid as Add on Therapy in Patients Receiving β Blocker for Prophylaxis of Moderate to Severe Migraine

PHASE2RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 25, 2022

Primary Completion Date

January 10, 2024

Study Completion Date

January 10, 2024

Conditions
Migraine Prophylaxis
Interventions
DRUG

Nicotinic Acid 500 MG Extended Release Oral Tablet

Nicotinic acid 500 mg for 12 weeks

DRUG

Nicotinic Acid 1000 MG Extended Release Oral Tablet

Nicotinic acid 1000 mg per day for 11 weeks, titrated from 500 mg/day for 1 week

OTHER

Placebo

Placebo 1000 mg per day for 11 weeks, titrated from 500 mg/day for 1 week

Trial Locations (1)

1000

RECRUITING

BSMMU, Dhaka

All Listed Sponsors
lead

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

OTHER